Freshly-appointed Auspherix CEO highlights new antibiotic class

November 24, 2016 Christoph Graener

 

Dr. Neil Miller, the recently-appointed CEO of UK-based biotech, Auspherix, talks to Scrip about the company’s new class of antibiotics and how it hopes to address the worldwide antimicrobial resistance crisis. Miller chats to Scrip senior writer, Lucie Ellis, about the science behind Auspherix’s gram-negative targeting new antibiotic class and the development timeline for the company’s preclinical assets. Miller was previously CSO of Auspherix, which is developing a novel class of organogold antibacterials. In parallel to Miller’s promotion, Auspherix has appointed Dr. Richard Rutter CSO and Dr. Paul King head of chemistry.

  

  

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Neil Miller – Chief Scientific Officer, Auspherix

 

Previous Article
eTheRNA CEO outlines development plan in cancer RNA space
eTheRNA CEO outlines development plan in cancer RNA space

Mike Ward interviews Dirk Reyn, CEO of eTheRNA, discussing eTheRNA's emerging cancer immunotherapy pipeline...

Next Article
BioNTech’s Sean Marett explains Genentech deal rationale
BioNTech’s Sean Marett explains Genentech deal rationale

Chief operating officer of BioNTech, Sean Marett, talks about the German firm's recent co-development deal ...